Danaher (DHR) Stock Forecast & Price Target

Q: What analysts cover Danaher?

Danaher has been rated by research analysts at Argus , Barclays , Citigroup , DZ Bank , Evercore , Guggenheim , HSBC , Jefferies Financial Group , JPMorgan Chase & Co. , Morgan Stanley , Robert W. Baird , Rothschild & Co Redburn , Royal Bank Of Canada , TD Cowen , The Goldman Sachs Group , UBS Group , Weiss Ratings , Wells Fargo & Company , and Wolfe Research in the past 90 days.

$185.16 -3.25 (-1.73%)

As of 01:52 PM Eastern

Compare

Danaher - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
4

Buy
20

Based on 24 Wall Street analysts who have issued ratings for Danaher in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 4 have given a hold rating, 19 have given a buy rating, and 1 has given a strong buy rating for DHR.

Consensus Price Target

$235.14
26.99% Upside

According to the 24 analysts' twelve-month price targets for Danaher, the average price target is $235.14. The highest price target for DHR is $275.00, while the lowest price target for DHR is $200.00. The average price target represents a forecasted upside of 26.99% from the current price of $185.16.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for DHR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Danaher and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DHR Analyst Ratings Over Time

Type	Current Forecast 6/10/25 to 6/10/26	1 Month Ago 5/11/25 to 5/11/26	3 Months Ago 3/12/25 to 3/12/26	1 Year Ago 6/10/24 to 6/10/25
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	19 Buy rating(s)	18 Buy rating(s)	20 Buy rating(s)	16 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$235.14	$240.70	$253.86	$248.17
Forecasted Upside	26.99% Upside	44.60% Upside	36.20% Upside	22.48% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

DHR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DHR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Danaher Stock vs. The Competition

Type	Danaher	Medical Companies	Broader Market
Consensus Rating Score	2.88	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	24.82% Upside	760.77% Upside	14.83% Upside
News Sentiment Rating	Positive News See Recent DHR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/3/2026	HSBC 3 of 5 stars	Rajesh Kumar Not Rated	Lower Target	Buy	$270.00 ➝ $230.00	+30.71%
6/3/2026	DZ Bank 4 of 5 stars		Initiated Coverage	Buy	$210.00	+19.34%
6/1/2026	Wolfe Research 3 of 5 stars	Mike Polark Not Rated	Downgrade	Outperform ➝ Peer Perform
5/26/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$230.00	+33.06%
5/14/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$200.00	+21.51%
4/24/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$265.00 ➝ $230.00	+29.72%
4/22/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kallum Titchmarsh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$270.00 ➝ $255.00	+38.50%
4/22/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$270.00 ➝ $250.00	+35.79%
4/22/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Overweight	$275.00 ➝ $245.00	+25.95%
4/22/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Couillard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$240.00 ➝ $212.00	+8.98%
Get the Latest News and Ratings for DHR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.
4/22/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$245.00 ➝ $240.00	+23.38%
4/22/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Subbu Nambi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$275.00 ➝ $235.00	+20.81%
4/21/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$245.00	+25.80%
4/21/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$225.00 ➝ $232.00	+19.27%
4/17/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Catherine Ramsey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$251.00 ➝ $249.00	+28.76%
4/17/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$205.00	+6.01%
4/14/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$250.00 ➝ $230.00	+17.38%
4/13/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evie Koslosky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$265.00 ➝ $230.00	+18.28%
3/27/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
1/29/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
1/29/2026	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
1/16/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$260.00 ➝ $270.00	+14.38%
9/22/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derik De Bruin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$230.00 ➝ $220.00	+15.24%
7/11/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sung Ji Nam Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$275.00	+33.79%
3/14/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$260.00	+27.48%
2/3/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Cooper Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
10/23/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$315.00 ➝ $315.00	+23.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:52 PM ET.

Should I Buy Danaher Stock? DHR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 8, 2026. Please send any questions or comments about these Danaher pros and cons to contact@marketbeat.com.

Danaher
Bull Case

Here are some ways that investors could benefit from investing in Danaher Co.:

Danaher Co. recently reported earnings per share (EPS) of $2.06, exceeding expectations, which indicates strong financial performance and potential for growth.
The company has a solid revenue stream, with a reported revenue of $5.95 billion for the latest quarter, showing a year-over-year increase of 3.7%.
Danaher Co. has a favorable dividend policy, recently announcing a quarterly dividend of $0.40 per share, which translates to an annualized yield of approximately 1.0%, appealing to income-focused investors.
The stock is currently priced around $175.97, which may present a buying opportunity for investors looking for value in a well-established company.
Analysts have a consensus rating of "Moderate Buy" for Danaher Co., with a significant number of analysts issuing buy ratings, suggesting positive market sentiment.

Danaher
Bear Case

Investors should be bearish about investing in Danaher Co. for these reasons:

The stock has experienced a decline of about 2.2% recently, which may indicate short-term volatility and potential risks for investors.
Analysts have adjusted their price targets downward, with some estimates dropping significantly, which could reflect concerns about future performance.
Danaher Co. has a relatively high price-to-earnings (P/E) ratio of 34.04, suggesting that the stock may be overvalued compared to its earnings, which could deter value investors.
The company has a debt-to-equity ratio of 0.33, which, while manageable, indicates some level of leverage that could pose risks in a rising interest rate environment.
Market conditions can be unpredictable, and any downturn in the life sciences or diagnostics sectors could adversely affect Danaher Co.'s performance.

DHR Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Danaher is $235.14, with a high forecast of $275.00 and a low forecast of $200.00.

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last twelve months. There are currently 4 hold ratings, 19 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DHR shares.

According to analysts, Danaher's stock has a predicted upside of 26.99% based on their 12-month stock forecasts.

Over the previous 90 days, Danaher's stock had 2 upgrades and 1 downgrade by analysts.

Danaher has been rated by research analysts at Argus, Barclays, Citigroup, DZ Bank, Evercore, Guggenheim, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Rothschild & Co Redburn, Royal Bank Of Canada, TD Cowen, The Goldman Sachs Group, UBS Group, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like Danaher more than other "medical" companies. The consensus rating for Danaher is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how DHR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Danaher Recommendations

This page (NYSE:DHR) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Danaher (DHR) Stock Forecast & Price Target